Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart — Barrons.com

By Mackenzie TatananniFoghorn Therapeutics said it would be slashing nearly half of its workforce after scrapping a drug development partnership with Eli Lilly, forcing the biotech into defensive mode as it attempts to conserve cash.The Massachusetts-based biotech, valued at roughly $212 million, a…